Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Biogen's first quarter 2024 earnings reflect the company's commitment to growth and innovation within its portfolio, coupled with an unwavering focus on improving profitability.</li><li>The company has seen growth in its earnings per share for the first time in several years, largely due to the performance of its underlying business.</li><li>CEO, Chris Viehbacher, praised the company’s teams for their commitment and the role they play in driving the company’s success, notwithstanding the ongoing changes within the company.</li></ul>

Biogen's first quarter 2024 earnings reflect the company's commitment to growth and innovation within its portfolio, coupled with an unwavering focus on improving profitability.The company has seen growth in its earnings per share for the first time in several years, largely due to the performance of its underlying business.CEO, Chris Viehbacher, praised the company’s teams for their commitment and the role they play in driving the company’s success, notwithstanding the ongoing changes within the company.

Biogen Inc.: Advancement of Neuroscience Drug Delivery & 6 Major Drivers

<ul><li>Biogen concluded its Fourth Quarter and Full Year 2023, announcing several positive strides and addressing potential drawback in its prospects moving forward with its outlook for 2024.</li><li>Biogen emphasized its objective of returning to sustainable growth.</li><li>Chris Viehbacher, Biogen's President and Chief Executive Officer, reported positive earnings per share guidance, a notable element for consideration.</li></ul>

Biogen concluded its Fourth Quarter and Full Year 2023, announcing several positive strides and addressing potential drawback in its prospects moving forward with its outlook for 2024.Biogen emphasized its objective of returning to sustainable growth.Chris Viehbacher, Biogen's President and Chief Executive Officer, reported positive earnings per share guidance, a notable element for consideration.

Biogen Inc: The Breakthrough Drug Portfolio Set to Dominate Neurology - See How They're Changing the Game! - Major Drivers

<ul><li>Biogen delivered a strong result and managed an all-around beat last quarter.</li><li>The last quarter saw decreased total revenue, but the company delivered a solid performance overall.</li><li>The decline in Multiple Sclerosis (MS) product revenues was due to generic entrants for TECFIDERA and intense competition in the MS market.</li></ul>

Biogen delivered a strong result and managed an all-around beat last quarter.The last quarter saw decreased total revenue, but the company delivered a solid performance overall.The decline in Multiple Sclerosis (MS) product revenues was due to generic entrants for TECFIDERA and intense competition in the MS market.

Biogen Inc: Job Cuts to Prioritize New Drug Launches. Genius or Misstep? – Key Drivers

<ul><li>Biogen had a successful first quarter with an all-around beat.</li><li>The company executed the launch of Leqembi, an immediate transformative product in the Alzheimer's disease therapeutic area.</li><li>Biogen has been experiencing a lot of competition, making it necessary to think about how to grow the business in the future.</li></ul>

Biogen had a successful first quarter with an all-around beat.The company executed the launch of Leqembi, an immediate transformative product in the Alzheimer's disease therapeutic area.Biogen has been experiencing a lot of competition, making it necessary to think about how to grow the business in the future.

Biogen Inc.: The Lecanemab Progress On The Alzheimer’s Front & Other Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/csl-ltd" target="_blank" data-smartkarma-citation="entities:917:1" rel="noopener">CSL Ltd (CSL AU)</a> is well-positioned to report double-digit revenue and profit growth through FY25, driven by strong performance of existing business and new growth engines.</li>
<li>CSL will launch FDA-approved gene therapy Hemgenix for Hemophilia B in the US in 2H23. With estimated global annual peak sales of $2.4B, Hemgenix is a compelling opportunity for CSL.</li>
<li>During H1FY23, CSL reported record level of plasma collections, with 36% growth in                volume. Current plasma collection is 10% above the pre-pandemic. Higher volume and yield will improve profitability.</li>
</ul>



CSL Ltd (CSL AU) is well-positioned to report double-digit revenue and profit growth through FY25, driven by strong performance of existing business and new growth engines.
CSL will launch FDA-approved gene therapy Hemgenix for Hemophilia B in the US in 2H23. With estimated global annual peak sales of $2.4B, Hemgenix is a compelling opportunity for CSL.
During H1FY23, CSL reported record level of plasma collections, with 36% growth in                volume. Current plasma collection is 10% above the pre-pandemic. Higher volume and yield will improve profitability.


CSL Ltd (CSL AU): Looking into New Engines for Sustainable and Profitable Growth

United States

Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biogen Inc (BIIB US)

Biogen Inc.: Advancement of Neuroscience Drug Delivery & 6 Major Drivers

Biogen's first quarter 2024 earnings reflect the company's commitment to growth and innovation within its portfolio, coupled with an unwavering...

Baptista Research

Biogen Inc: The Breakthrough Drug Portfolio Set to Dominate Neurology - See How They're Changing the Game! - Major Drivers

Biogen concluded its Fourth Quarter and Full Year 2023, announcing several positive strides and addressing potential drawback in its prospects...

Baptista Research

Biogen Inc: Job Cuts to Prioritize New Drug Launches. Genius or Misstep? – Key Drivers

Biogen delivered a strong result and managed an all-around beat last quarter. The last quarter saw decreased total revenue, but the company...

Baptista Research

Biogen Inc.: The Lecanemab Progress On The Alzheimer’s Front & Other Drivers

Biogen had a successful first quarter with an all-around beat. The company executed the launch of Leqembi, an immediate transformative product in...

Baptista Research

CSL Ltd (CSL AU): Looking into New Engines for Sustainable and Profitable Growth

New management, upcoming product launch in US, diversification into kidney disease, plasma collection recovery, and rich pipeline indicate an...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)